NorthWest Biotherapeutics Inc (NWBO)

[LearningEveryTrade]

2018 NICE says this re: DCVAX-L cost-effectiveness
"Economic analysis The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.
The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.
Costs will be considered from an NHS and Personal Social Services perspective."

https://www.sps.nhs.uk/medicines/canpuldencel-t/ near bottom, click NICE Scope, words are in green, as 2018 PDF opens.

I see the "cost per QALY" as being important, given good 5 year survival data. 200K/5 years is cheaper than generic SOC. IMHO.